Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab

  • Aasem Abu Shtaya epartment of Internal Medicine “B”, Lady Davis Carmel Medical Center, Haifa, Israel; Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel
  • Shai Cohen Department of Internal Medicine “B”, Lady Davis Carmel Medical Center, Haifa, Israel; Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel
  • Yana Kogan Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Pulmonology Institute and CF center, Lady Davis Carmel Medical Center, Haifa, Israel
  • Michal Shteinberg Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Pulmonology Institute and CF center, Lady Davis Carmel Medical Center, Haifa, Israel
  • Ori Sagol Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Department of Gastroenterology, Lady Davis Carmel Medical Center, Haifa, Israel
DOI: https://doi.org/10.12890/2021_002265

Keywords

Crohn’s disease, granuloma, vedolizumab, infliximab

Abstract

Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn’s disease. Here, we present a patient with Crohn’s disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.

VIEW THE ENTIRE ARTICLE

References

  • Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn’s disease. World J Gastroenterol 2014;20(1):133–141.
  • MacDermott RP, Nash GS, Nahm MH. Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients. Immunol Invest 1989;18(1–4):449–457.
  • Bienenstock J, McDermott M, Befus D, O’Neill M. A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol 1978;107:53–59.
  • Chew MT, Chak E, Matsukuma K. A rare cause of pulmonary nodules. Case Rep Gastroenterol 2016;10(3):633–639.
  • Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, et al. Pulmonary manifestation of Crohn’s disease developed under treatment with vedolizumab. Am J Gastroenterol 2018;113(1):146–148.

    • Published: 2021-02-19

    Issue: Vol 8 No 2 (view)

    Section: Articles

    How to cite:
    1.
    Abu Shtaya A, Cohen S, Kogan Y, Shteinberg M, Sagol O. Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab. EJCRIM 2021;8 doi:10.12890/2021_002265.

    Most read articles by the same author(s)